The company reported its results for the quarter ended September 2022 more than a month ago.īristol Myers reported revenues of $11.22 billion in the last reported quarter, representing a year-over-year change of -3.5%. Over the past month, Bristol Myers Squibb (BMY), a stock from the same industry, has gained 3.7%. We expect an in-line return from the stock in the next few months.īlueprint Medicines is part of the Zacks Medical - Biomedical and Genetics industry. Notably, Blueprint Medicines has a Zacks Rank #3 (Hold). If you aren't focused on one strategy, this score is the one you should be interested in.Įstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Overall, the stock has an aggregate VGM Score of F. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy. The consensus estimate has shifted -8.9% due to these changes.Ĭurrently, Blueprint Medicines has a poor Growth Score of F, a grade with the same score on the momentum front. It turns out, estimates revision have trended downward during the past month. How Have Estimates Been Moving Since Then? Net Ayvakit revenues are expected to be $108-$111 million for 2022 compared with the earlier mentioned $115-$130 million. Research and development expenses were $128 million, up 51.6% from the year-ago figure, owing to higher costs associated with clinical studies and increased costs due to early discovery efforts. The year-over-year surge in total revenues can be attributed to license revenues. License revenues from the related party were $27.5 million in the third quarter of 2022. Sales of the drug grew slightly on a sequential basis and 65.8% on a year-over-year basis.Ĭollaboration revenues were $9.8 million, primarily generated from the agreements with CStone Pharmaceutical and Roche. Net product revenues from Ayvakit sales were $28.6 million. product sales of Gavreto (pralsetinib) to Roche on Jul 1, 2021, Blueprint Medicines only records its share of profits for the drug in its financial results.īlueprint Medicines’ total revenues of $66 million comprised net product revenues from Ayvakit sales, collaboration revenues and license revenues-related party. Since the company has transferred the responsibilities of booking U.S. Total revenues were higher than our estimate of $43.9 million in the reported quarter. Sales were up significantly from the year-ago figure of $24.2 million. Quarterly revenues of $66 million also surpassed the Zacks Consensus Estimate of $43 million. The company reported a loss of $2.00 per share in the year-ago quarter. The loss was also narrower than our estimate of a loss of $2.44 per share. Blueprint Medicines' Q3 Earnings & Revenues Top Markīlueprint Medicines reported a loss of $2.23 per share for third-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $2.51. Will the recent positive trend continue leading up to its next earnings release, or is Blueprint Medicines due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Shares have added about 3.7% in that time frame, underperforming the S&P 500. A month has gone by since the last earnings report for Blueprint Medicines (BPMC).
0 Comments
Leave a Reply. |